N-tert-butyl-6-chloro-2-nitroaniline | 148858-01-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-tert-butyl-6-chloro-2-nitroaniline
• 英文别名: tert-butyl-(2-chloro-6-nitrophenyl)amine；N-tert-butyl-2-chloro-6-nitroaniline
• CAS: 148858-01-9
• 化学式: C₁₀H₁₃ClN₂O₂
• 分子量: 228.678
• InChiKey: HXWUGEATISVHBK-UHFFFAOYSA-N

物化性质

• 沸点：
  322.9±27.0 °C(Predicted)
• 密度：
  1.254±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  57.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-tert-butyl-6-chloro-2-nitroaniline 在 镍 硫酸 、 potassium tert-butylate 、 一水合肼 、 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 四氢呋喃 、 乙醇 、 水 、 乙腈 为溶剂， 反应 57.5h， 生成 6-chloro-3-(5-cyclopropyl-1,2,4-oxadiazol-3-yl)-4,5-dihydroimidazo<1,5-a>quinoxaline
  参考文献：
  名称：

  High-Affinity Partial Agonist Imidazo[1,5-a]quinoxaline Amides, Carbamates, and Ureas at the γ-Aminobutyric Acid A/Benzodiazepine Receptor Complex

  摘要：

  A series of imidazo[1,5-alpha]quinoxaline amides, carbamates, and ureas which have high affinity for the gamma-aminobutyric acid A/benzodiazepine receptor complex was developed. Compounds within this class have varying efficacies racing from antagonists to full agonists. However, most analogs were found to be partial agonists as indicated by [S-35]TBPS and Cl- current ratios. Many of these compounds were also effective in antagonizing metrazole-induced seizures in accordance with anticonvulsant and possible anxiolytic activity. Selected quinoxalines displayed limited benzodiazepine-type side effects such as ethanol potentiation and physical dependence in animal models. Dimethylamino urea 41 emerged as the most interesting analog, having a partial agonist profile in vitro while possessing useful activity in animal models of anxiety such as the Vogel and Geller assays. In accordance with its partial agonist profile, 41 was devoid of typical benzodiazepine side effects.

  DOI：

  10.1021/jm940765f
• 作为产物：
  描述：

  2,3-二氯硝基苯 在 叔丁胺 作用下， 以 乙醇 为溶剂， 生成 N-tert-butyl-6-chloro-2-nitroaniline
  参考文献：
  名称：

  Imidazo[1,5-A]quinoxalines

  摘要：

  一种涉及咪唑并[1,5-a]喹喔啉(I)的发明，不含内环羰基，并且可用作抗焦虑和镇静/催眠剂。

  公开号：

  US05541324A1

文献信息

• [EN] HETEROCYCLIC CONDENSED COMPOUNDS USEFUL AS ANTIDIURETIC AGENTS<br/>[FR] COMPOSES CONDENSES HETEROCYCLIQUES UTILISES EN TANT QU'ANTIDIURETIQUES
  申请人：FERRING BV

  公开号：WO2006018443A1

  公开（公告）日：2006-02-23

  The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  这项发明涉及通式1中的化合物，其中G1是胺基。根据该发明的化合物是抗利尿激素V2受体激动剂。这些化合物的药物组合物可用作抗利尿剂。
• 4,5-cyclicimidazo[1,5-A]quinoxalines
  申请人：Pharmacia & Upjohn Company

  公开号：US05668282A1

  公开（公告）日：1997-09-16

  The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.

  本发明揭示了不含内环羰基的咪唑[1,5-a]喹啉(I) ##STR1## 作为抗焦虑和镇静/催眠剂使用。
• 5,6-cyclicimidazo [1,5-a] Quinoxalines
  申请人：The Upjohn Company

  公开号：US05574038A1

  公开（公告）日：1996-11-12

  The invention discloses imidazo[1,5-a]quinoxalines (I) ##STR1## which do not contain an endocyclic carbonyl group that are useful as anxiolytic and sedative/hypnotic agents.

  本发明揭示了不含内环羰基的咪唑并[1,5-a]喹啉(I) ##STR1## 作为抗焦虑和镇静/催眠剂。
• Heterocyclic Condensed Compounds Useful as Antidiuretic Agents
  申请人：Pitt Gary Robert William

  公开号：US20080234250A1

  公开（公告）日：2008-09-25

  The invention concerns compounds according to general formulae 1, wherein G 1 is an amine. Compounds according to the invention are vasopressin V 2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  该发明涉及一般式1中G1为胺基的化合物。根据该发明的化合物是利尿激素V2受体激动剂。该化合物的药物组成物作为抗利尿剂是有用的。
• Heterocyclic condensed compounds useful as antidiuretic agents
  申请人：Vantia Limited

  公开号：US08063038B2

  公开（公告）日：2011-11-22

  The invention concerns compounds according to general formulae 1, wherein G1 is an amine. Compounds according to the invention are vasopressin V2 receptor agonists. Pharmaceutical compositions of the compounds are useful as antidiuretic agents.

  本发明涉及一般式1中G1为胺基的化合物。本发明的化合物是加压素V2受体激动剂。所述化合物的制药组合物可用作抗利尿剂。